ABSTRACT
Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an in-house proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (1), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacologically relevant doses with good ADME properties, and achieved >90% inhibition of BTK phosphorylation (pBTK) in humans.
Subject(s)
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Pyrimidines/chemistry , Administration, Oral , Agammaglobulinaemia Tyrosine Kinase/metabolism , Animals , Antigens, T-Independent/chemistry , Antigens, T-Independent/metabolism , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Binding Sites , Catalytic Domain , Dogs , Drug Evaluation, Preclinical , Female , Half-Life , Humans , Mice , Microsomes, Liver/metabolism , Molecular Dynamics Simulation , Protein Kinase Inhibitors/metabolism , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/metabolism , Pyrimidines/therapeutic use , Rats , Structure-Activity RelationshipABSTRACT
Protein interacting with C kinase (PICK1) is a scaffolding protein that is present in dendritic spines and interacts with a wide array of proteins through its PDZ domain. The best understood function of PICK1 is regulation of trafficking of AMPA receptors at neuronal synapses via its specific interaction with the AMPA GluA2 subunit. Disrupting the PICK1-GluA2 interaction has been shown to alter synaptic plasticity, a molecular mechanism of learning and memory. Lack of potent, selective inhibitors of the PICK1 PDZ domain has hindered efforts at exploring the PICK1-GluA2 interaction as a therapeutic target for neurological diseases. Here, we report the discovery of PICK1 small molecule inhibitors using a structure-based drug design strategy. The inhibitors stabilized surface GluA2, reduced Aß-induced rise in intracellular calcium concentrations in cultured neurons, and blocked long term depression in brain slices. These findings demonstrate that it is possible to identify potent, selective PICK1-GluA2 inhibitors which may prove useful for treatment of neurodegenerative disorders.
Subject(s)
Amyloid beta-Peptides/metabolism , Brain/metabolism , Carrier Proteins/antagonists & inhibitors , Dendritic Spines/metabolism , Neurodegenerative Diseases/metabolism , Nuclear Proteins/antagonists & inhibitors , Synapses/metabolism , Animals , Brain/pathology , Calcium/metabolism , Calcium Signaling , Carrier Proteins/metabolism , Cell Cycle Proteins , Dendritic Spines/pathology , Drug Design , Mice , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/pathology , Nuclear Proteins/metabolism , PDZ Domains , Receptors, AMPA/metabolism , Synapses/pathologyABSTRACT
Amyloid beta (Aß), a key component in the pathophysiology of Alzheimer's disease, is thought to target excitatory synapses early in the disease. However, the mechanism by which Aß weakens synapses is not well understood. Here we showed that the PDZ domain protein, protein interacting with C kinase 1 (PICK1), was required for Aß to weaken synapses. In mice lacking PICK1, elevations of Aß failed to depress synaptic transmission in cultured brain slices. In dissociated cultured neurons, Aß failed to reduce surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit 2, a subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors that binds with PICK1 through a PDZ ligand-domain interaction. Lastly, a novel small molecule (BIO922) discovered through structure-based drug design that targets the specific interactions between GluA2 and PICK1 blocked the effects of Aß on synapses and surface receptors. We concluded that GluA2-PICK1 interactions are a key component of the effects of Aß on synapses.
Subject(s)
Amyloid beta-Peptides/toxicity , Carrier Proteins/metabolism , Excitatory Postsynaptic Potentials , Nuclear Proteins/metabolism , Peptide Fragments/toxicity , Synapses/metabolism , Animals , Carrier Proteins/genetics , Cell Cycle Proteins , Cells, Cultured , Hippocampus/cytology , Hippocampus/metabolism , Hippocampus/physiology , Mice , Neurons/drug effects , Neurons/metabolism , Neurons/physiology , Nuclear Proteins/genetics , Protein Binding , Rats , Receptors, AMPA/metabolism , Synapses/drug effects , Synapses/physiologyABSTRACT
Polytriazolylamines were synthesized by the copper(I)-catalyzed ligation of azides and alkynes. The C3-symmetric derivative, TBTA, was shown to be a powerful stabilizing ligand for copper(I), protecting it from oxidation and disproportionation, while enhancing its catalytic activity.
Subject(s)
Copper/chemistry , Polymers/chemistry , Triazoles/chemistry , Amines/chemistry , Catalysis , Ligands , Molecular Structure , Oxidation-ReductionABSTRACT
The copper-catalyzed cycloaddition reaction between azides and alkynes functions efficiently in aqueous solution in the presence of a tris(triazolyl)amine ligand. The process has been employed to make rapid and reliable covalent connections to micromolar concentrations of protein decorated with either of the reactive moieties. The chelating ligand plays a crucial role in stabilizing the Cu(I) oxidation state and protecting the protein from Cu(triazole)-induced denaturation. Because the azide and alkyne groups themselves are unreactive with protein residues or other biomolecules, their ligation is of potential utility as a general bioconjugation method.
